用于癌症过继细胞治疗的综合治疗性 T 细胞受体筛选平台-猫眼课题宝

用于癌症过继细胞治疗的综合治疗性 T 细胞受体筛选平台

批准号：

9678342

负责人：

Ning Jenny Jiang

金额：

$1.28万

依托单位：

UNIVERSITY OF TEXAS AT AUSTIN

依托单位国家：

美国

项目类别：

财政年份：

2018

资助国家：

美国

项目状态：

已结题

起止时间：

2018-04-04 至 2021-03-31

来源：

https://reporter.nih.gov/project-details/9678342

关键词：

Adoptive Cell Transfers Affinity Animal Model Antigen Targeting Antigens Area Blood donor CD8-Positive T-Lymphocytes CTAG1 gene Cancer cell line Cell Culture Techniques Cell Line Cell physiology Cells Clinical Clinical Research Clinical Trials Elements Epitopes Expression Profiling Foundations Future Gene Expression Genes Goals Human Immunotherapy In Situ KRAS2 gene Libraries Magic Malignant Neoplasms Manuscripts Measurement Membrane Memorial Sloan-Kettering Cancer Center Methods Mus Mutate Mutation Names Organoids Patients Process Protein Engineering Research Sampling Speed Surface Plasmon Resonance T-Cell Receptor T-Lymphocyte Technology Testing Therapeutic Tumor Antigens Validation base cancer cell cancer immunotherapy clinical practice combinatorial cross reactivity cytotoxicity cytotoxicity test driver mutation effectiveness testing efficacy testing individual patient neoantigens patient screening peripheral blood pre-clinical prevent screening success technology development therapeutic evaluation tool tumor

项目摘要

项目成果

Ning Jenny Jiang的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

Abstract Recent successes of T cell receptor based adoptive cell transfer therapy have generated new excitement about this therapeutic approach. However, lacking a high-throughput method of screening of naturally occurring high- affinity therapeutic T cell receptors (TCRs) has put a limit on how widely this approach can be applied to different kinds of cancers and a large range of patients. In this study, we propose to develop an integrated platform that on one hand drastically speeds up the identification and test of therapeutic TCRs and on the other hand, profiles common cancer antigens and HLAs expressed in tumor sample at single cell level. We name it Magic-HAT for Matching antigen identification in cancer with High-Affinity TCRs. The success of this project breaks the bottleneck of identifying and testing naturally occurring therapeutic high-affinity TCRs in adoptive cell transfer therapy setting for a large panel of cancer antigen epitopes. It enables a new capability on using combination of TCRs in TCR-redirected T cells for adoptive cell transfer therapy in cancer.

期刊论文(0)

专著(0)

科研奖励(0)

会议论文